Swiss drugmaker Actelion says that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension of indication for the use of Zavesca (miglustat) in patients suffering from Niemann-Pick type C, a very rare neurodegenerative genetic disease.
Based on the CHMP opinion, the European Commission is expected to make a final decision within two months. Actelion is currently evaluating the possibility for submissions for the agent in NPC in other countries outside the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze